As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the deadline for submissions is now 9 February 2022.
These timelines are based on a request from the company to reschedule in order to facilitate a suitably comprehensive and robust submission.